Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates
March 27, 2023 07:50 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported...
Vaxxinity Joins TransCelerate Research and Development Consortium
March 21, 2023 08:00 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., March 21, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced today that...
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia
March 20, 2023 08:00 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., March 20, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that...
Vaxxinity to Present at Upcoming March Scientific and Medical Conferences
March 02, 2023 08:00 ET
|
Vaxxinity, Inc.
CAPE CANAVERAL, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that...
Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida
February 01, 2023 19:40 ET
|
Vaxxinity, Inc.
Appointment of new directors bring diversity, balance and relevant industry expertise to Vaxxinity Establishment of Frontier Exploration Laboratories (“VaxxLabs”) in Cape Canaveral, Fla., as...
Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference
January 05, 2023 08:00 ET
|
Vaxxinity, Inc.
DALLAS, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu,...
Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612
December 02, 2022 08:00 ET
|
Vaxxinity, Inc.
Vaxxinity’s next-generation COVID-19 booster candidate UB-612 achieves primary and key secondary immunogenicity endpoints in a pivotal head-to-head heterologous booster trial against three authorized...
Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 10, 2022 07:30 ET
|
Vaxxinity, Inc.
Phase 1 Part B End-of-Treatment Data Show UB-312 is Well Tolerated and Immunogenic in Parkinson’s Disease Patients VXX-401 Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in...
Vaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022
November 03, 2022 08:00 ET
|
Vaxxinity, Inc.
Featuring subject matter experts in neuroscience, migraine and hypercholesterolemia DALLAS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the...
Vaxxinity to Present at Upcoming Investor Conferences in November
November 01, 2022 09:00 ET
|
Vaxxinity, Inc.
DALLAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu,...